- Tytuł:
- Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial
- Autorzy:
- Źródło:
- In The Lancet Infectious Diseases August 2022 22(8):1131-1141
Czasopismo naukowe